BVNRY (Bavarian Nordic AS) FCF Margin % : 15.50% (As of Dec. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Bavarian Nordic AS FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bavarian Nordic AS's Free Cash Flow for the three months ended in Dec. 2024 was $45.6 Mil. Bavarian Nordic AS's Revenue for the three months ended in Dec. 2024 was $294.0 Mil. Therefore, Bavarian Nordic AS's FCF Margin % for the quarter that ended in Dec. 2024 was 15.50%.

As of today, Bavarian Nordic AS's current FCF Yield % is 2.20%.

The historical rank and industry rank for Bavarian Nordic AS's FCF Margin % or its related term are showing as below:

BVNRY' s FCF Margin % Range Over the Past 10 Years
Min: -444.83 Med: -2.64 Max: 17.49
Current: 4.25

During the past 13 years, the highest FCF Margin % of Bavarian Nordic AS was 17.49%. The lowest was -444.83%. And the median was -2.64%.

BVNRY's FCF Margin % is ranked better than
80.63% of 1012 companies
in the Biotechnology industry
Industry Median: -129.705 vs BVNRY: 4.25

Bavarian Nordic AS FCF Margin % Historical Data

The historical data trend for Bavarian Nordic AS's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bavarian Nordic AS FCF Margin % Chart

Bavarian Nordic AS Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

FCF Margin %

Get a 7-Day Free Trial

-7.28

-74.66

-36.86

2.01

4.59

Bavarian Nordic AS Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
FCF Margin %	Get a 7-Day Free Trial															13.95	51.54	-1.43	-34.51	15.50

Competitive Comparison of Bavarian Nordic AS's FCF Margin %

For the Biotechnology subindustry, Bavarian Nordic AS's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bavarian Nordic AS's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bavarian Nordic AS's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bavarian Nordic AS's FCF Margin % falls into.

Save Embed

;

Save Embed

;

Bavarian Nordic AS FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bavarian Nordic AS's FCF Margin for the fiscal year that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2024 )	/	Revenue (A: Dec. 2024 )
	=	36.814	/	802.601
	=	4.59 %

Bavarian Nordic AS's FCF Margin for the quarter that ended in Dec. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2024 )	/	Revenue (Q: Dec. 2024 )
	=	45.566	/	293.997
	=	15.50 %

Bavarian Nordic AS FCF Margin % Related Terms

Thank you for viewing the detailed overview of Bavarian Nordic AS's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bavarian Nordic AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bavarian Nordic AS (OTCPK:BVNRY) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BVNKF:USA 0DPB:UK BAVA:Denmark BV3:Germany BAVA:Austria

Address

Philip Heymans Alle 3, Hellerup, DNK, 2900

Website

https://www.bavarian-nordic.com

Bavarian Nordic AS is a biotechnology company focused on the research, development, manufacturing, and commercialization of life-saving vaccines. The vast majority of the company's revenue is generated in the United States, Germany, and other geographic markets. Its products include Encepur, Jynneos, Rabipur, Vaxchora and Vivotif.